je.st
news
Tag: therapy
Mercks Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Nave Adults
2014-03-05 18:15:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the companys investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
activity
phase
adults
Dutch gene therapy pioneer raises $82 million in U.S. IPO
2014-02-06 03:56:42| Biotech - Topix.net
A small Dutch company behind the Western world's first approved gene therapy priced its shares above the expected range in a U.S. stock offering on Wednesday, showing the current investor appetite for biotechnology.
Tags: us
million
therapy
dutch
Researchers Open Door to New HIV Therapy
2014-01-29 22:28:17| Biotech - Topix.net
People infected with the Human Immunodeficiency Virus can stave off the symptoms of AIDS thanks to drug cocktails that mainly target three enzymes produced by the virus, but resistant strains pop up periodically that threaten to thwart these drug combos.
Tags: open
door
therapy
researchers
Varian Medical Systems Receives FDA 510(k) Clearance for Its ProBeam(TM) Proton Therapy System
2014-01-15 06:00:00| Industrial Newsroom - All News for Today
PALO ALTO, Calif. — Varian Medical Systems (NYSE: VAR) has received FDA 510(k) clearance for its updated ProBeam™ proton therapy system.<br /> <br /> Varian's ProBeam system gives clinicians options for delivering dose precisely in order to minimize dose to healthy tissue in the course of delivering proton therapy treatments for cancer. Its scanning beam technology enables intensity-modulated proton therapy (IMPT) by modulating dose levels on a spot-by-spot basis throughout the ...This story is related to the following:Radiotherapy Systems
Tags: system
systems
medical
therapy
01.03.14 -- Five Potential Cancer Targets For Antibody Drug Conjugate Therapy Discovered
2013-12-31 00:29:39| drugdiscoveryonline News Articles
01/03/14Drug Discovery Online Newsletter
Tags: potential
drug
cancer
therapy
Sites : [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] next »